Emend For Oral Suspension Generic Name & Formulations
Aprepitant 125mg; per pouch; pwd for oral susp after reconstitution.
Substance P/NK1 receptor antagonist.
Caps—6; Bi-fold pack (2 x 80mg)—1; Tri-fold pack (1 x 125mg + 2 x 80mg)—1; Susp kit—1 (w. oral dispensers, supplies); Single-dose vial—1
Emend For Oral Suspension Indications
In combination with other antiemetic agents, in patients ≥6mos of age for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin.
Emend For Oral Suspension Dosage and Administration
Adults and Children
<6mos or <6kg: not recommended. Give with corticosteroid and 5-HT3 antagonist (see full labeling). 6mos–<12yrs or patients (Peds or Adults) unable to swallow: 3mg/kg (max 125mg) on Day 1; then 2mg/kg (max 80mg) on Days 2 and 3. Administer susp 1hr prior to chemotherapy on Days 1, 2, and 3; if no chemotherapy is given on Days 2 and 3, administer susp in the AM.
Emend For Oral Suspension Contraindications
Emend For Oral Suspension Boxed Warnings
Emend For Oral Suspension Warnings/Precautions
Not for chronic continuous use. Severe hepatic impairment. Injection: monitor for infusion site or hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms (eg, flushing, erythema, dyspnea, hypotension, syncope) develop with first-time use. Avoid infusion into small veins or through a butterfly catheter. Elderly. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (see Interactions). Pregnancy. Nursing mothers.
Emend For Oral Suspension Pharmacokinetics
Emend For Oral Suspension Interactions
See Contraindications. Monitor, and caution with, CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine). Avoid concomitant moderate-to-strong CYP3A4 inhibitors (eg, azole antifungals, macrolides, nefazodone, ritonavir, nelfinavir, diltiazem) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each regimen), other CYP2C9 substrates, oral contraceptives (use alternative or backup method during and for 1 month after last dose).
Emend For Oral Suspension Adverse Reactions
Fatigue, diarrhea, asthenia, dyspepsia, abdominal pain, hiccups, WBC count decreased, dehydration, ALT/AST increased, neutropenia, headache, anorexia, cough, hemoglobin decreased, dizziness, constipation, hypotension. Injection: also anemia, peripheral neuropathy, UTI, extremity pain, infusion-site reactions, anaphylaxis.
Emend For Oral Suspension Clinical Trials
Emend For Oral Suspension Note
Emend For Oral Suspension Patient Counseling